Selective and potent morpholinone inhibitors of the MDM2-p53 interaction

被引：0

作者：

Gonzalez, Ana Z. ^{[1
]}

Eksterowics, John ^{[1
]}

Beck, Hilary P. ^{[1
]}

Canon, Jude ^{[4
]}

Chen, Ada ^{[1
]}

Chow, David ^{[1
]}

Duquette, Jason ^{[1
]}

Fox, Brian M. ^{[1
]}

Fu, Jiasheng ^{[1
]}

Houze, Jonathan ^{[1
]}

Jin, Lixia ^{[1
]}

Li, Yihong ^{[1
]}

Li, Zhihong ^{[1
]}

Lo, Mei-Chu ^{[1
]}

Long, Alexander M. ^{[5
]}

McGee, Lawrence R. ^{[1
]}

McIntosh, Joel ^{[1
]}

Oliner, Jonathan D. ^{[4
]}

Osgood, Tao ^{[4
]}

Rew, Yosup ^{[1
]}

Saiki, Anne Y. ^{[4
]}

Shaffer, Paul ^{[5
]}

Wortman, Sarah ^{[2
]}

Yakowek, Peter ^{[5
]}

Yan, Xuelei ^{[1
]}

Ye, Qiuping ^{[3
]}

Yu, Dongyin ^{[4
]}

Zhao, Xiaoning ^{[1
]}

Zhou, Jing ^{[1
]}

Olson, Steven H. ^{[1
]}

Medina, Julio C. ^{[1
]}

Sun, Daqing ^{[1
]}

机构：

[1] Amgen Inc, Dept Therapeut Discovery, San Francisco, CA 94080 USA

[2] Amgen Inc, Pharmaceut, San Francisco, CA 94080 USA

[3] Amgen Inc, Dept Therapeut Discovery, Thousand Oaks, CA 91320 USA

[4] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA

[5] Amgen Inc, Dept Therapeut Discovery, Cambridge, MA 02142 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2013年 / 246卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

引用

页数：1

共 50 条

[1] Selective and Potent Morpholinone Inhibitors of the MDM2-p53 Protein-Protein Interaction
Gonzalez, Ana Z.
Eksterowicz, John
Bartberger, Michael D.
Beck, Hilary P.
Canon, Jude
Chen, Ada
Chow, David
Duquette, Jason
Fox, Brian M.
Fu, Jiasheng
Huang, Xin
Houze, Jonathan B.
Jin, Lixia
Li, Yihong
Li, Zhihong
Ling, Yun
Lo, Mei-Chu
Long, Alexander M.
McGee, Lawrence R.
McIntosh, Joel
McMinn, Dustin L.
Oliner, Jonathan D.
Osgood, Tao
Rew, Yosup
Saiki, Anne Y.
Shaffer, Paul
Wortman, Sarah
Yakowec, Peter
Yan, Xuelei
Ye, Qiuping
Yu, Dongyin
Zhao, Xiaoning
Zhou, Jing
Olson, Steven H.
Medina, Julio C.
Sun, Daqing
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (06) : 2472 - 2488
[2] Inhibitors of the MDM2-p53 interaction as anticancer drugs
Hardcastle, Ian R.
DRUGS OF THE FUTURE, 2007, 32 (10) : 883 - 896
[3] The MDM2-p53 interaction
Moll, UM
Petrenko, O
MOLECULAR CANCER RESEARCH, 2003, 1 (14) : 1001 - 1008
[4] Potent and Orally Active Small-Molecule Inhibitors of the MDM2-p53 Interaction
Yu, Shanghai
Qin, Dongguang
Shangary, Sanjeev
Chen, Jianyong
Wang, Guoping
Ding, Ke
McEachern, Donna
Qiu, Su
Nikolovska-Coleska, Zaneta
Miller, Rebecca
Kang, Sanmao
Yang, Dajun
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (24) : 7970 - 7973
[5] Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction
Yu, Ming
Wang, Yingcai
Zhu, Jiang
Bartberger, Michael D.
Canon, Jude
Chen, Ada
Chow, David
Eksterowicz, John
Fox, Brian
Fu, Jiasheng
Gribble, Michael
Huang, Xin
Li, Zhihong
Liu, Jiwen
Lo, Mei-chu
McMinn, Dustin
Oliner, Jonathan D.
Osgood, Tao
Rew, Yosup
Saiki, Anne Y.
Shaffer, Paul
Yan, Xuelei
Ye, Qiuping
Yu, Dongyin
Zhao, Xiaoning
Zhou, Jing
Olson, Steven H.
Medina, Julio C.
Sun, Daqing
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (08): : 894 - 899
[6] The development of piperidinones as potent MDM2-P53 protein - protein interaction inhibitors for cancer therapy
Liao, Guochao
Yang, Deying
Ma, Leilei
Li, Wenwei
Hu, Liqin
Zeng, Liming
Wu, Peng
Duan, Lixin
Liu, Zhongqiu
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 159 : 1 - 9
[7] Identification of substituted isoindolinones as potent inhibitors of the MDM2-p53 protein-protein interaction
Watson, Anna
Liu, Junfeng
Armstrong, Elizabeth
Blackburn, Timothy
Endicott, Jane A.
Golding, Bernard T.
Griffin, Roger J.
Lu, Xiaohong
Newell, David R.
Noble, Martin E. M.
Riedinger, Christiane
Lunec, John
Hardcastle, Ian R.
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[8] Targeting the MDM2-p53 interaction: evaluation of a novel, potent MDM2-p53 antagonist in patient-derived CLL cells
Willmore, Elaine
Aptullahoglu, Erhan
Zhao, Yan
Kyle, Suzanne
Thomas, Huw
Ahn, Maria
Fazal, Lynsey
Noble, Martin
Hardcastle, Ian
Howard, Steven
Chessari, Gianni
Lunec, John
Wedge, Steve
LEUKEMIA & LYMPHOMA, 2020, 61 : 81 - 81
[9] Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
Thayer, Kelly M.
Beyer, George A.
PLOS ONE, 2016, 11 (03):
[10] Development of a potent class of small molecule inhibitors of the MDM2-p53 protein-protein interaction
Fazal, Lynsey
Ahn, Maria
Bevan, Luke
Buck, Ildiko
Castro, Juan
Chessari, Gianni
Cons, Ben
Hearn, Keisha
Howard, Steven
Johnson, Chris
Reeks, Judith
Tamanini, Emiliano
Thompson, Neil
Walton, Hugh
Williams, Pamela
Bawn, Ruth H.
Blackburn, Tim J.
Cano, Celine
Cully, Sarah J.
Golding, Bernard
Griffin, Roger
Haggerty, Karen
Hardcastle, Ian
Newell, Herbie
Noble, Martin
Thomas, Huw
Willmore, Elaine
Zhao, Yan
Wedge, Steve
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →